Results 151 to 160 of about 46,440 (207)

Lefamulin or moxifloxacin for community-acquired pneumonia: balancing innovation, safety, and evidence. [PDF]

Ann Med Surg (Lond)
Wasti SA, Wasti A, Iqbal MU, Danaf N.
europepmc   +1 more source

Efficacy of regimens targeting Mycobacterium abscessus in vitro and in vivo. [PDF]

BMC Microbiol
Wang Z, Ye Y, Zhang W, Wang B, Chen X, Lu Y.   +5 more
europepmc   +1 more source

Effects of Cipepofol on Cardiac Depolarization and Repolarization in Healthy Subjects: A Single-Center, Randomized, Placebo and Positive-Controlled Thorough QT Study. [PDF]

Drug Des Devel Ther
Kleiman R, Rudo T, Daley W, Hu M, Yan P, Zhou R, Hou J.   +6 more
europepmc   +1 more source

Post anaphylactic shock myocardial infarction (Kounis syndrome): a rare case report. [PDF]

Ann Med Surg (Lond)
Abadi A, Ghanem U, Nierat S, Joma M.
europepmc   +1 more source

[Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium : Therapeutic challenges driven by antimicrobial resistance]. [PDF]

Dermatologie (Heidelb)
Kogler A, Chromy D, Sadoghi B.
europepmc   +1 more source

Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial. [PDF]

EClinicalMedicine
File TM, Kaye KS, Ihor S, Hovbakh I, Katsarava V, Kirsch C, Soni K, Gupta K, Manley A, Deck DH, Anastasiou D, Chitra S, Villano S.   +12 more
europepmc   +1 more source

Antimicrobial susceptibility and adaptative changes in MRSA lineages exposed to increasing concentrations of fluoroquinolones and chlorhexidine. [PDF]

Sci Rep
de Oliveira TLR, de Souza AF, de Souza BM, da Silva MG, Duarte RS, Ferreira RBR, Dos Santos KRN.   +6 more
europepmc   +1 more source

Acceptability of 100-mg moxifloxacin in children with rifampicin-resistant TB in three high-burden countries. [PDF]

IJTLD Open
Suryavanshi N, Draper HR, Dhumal G, Bagchi S, Castillo-Carandang NT, Marthinus A, Cheong AMA, Kinikar A, Paradkar M, Gupta A, Ocampo JDR, Frias MVG, Casalme DJO, Hesseling A, Garcia-Prats AJ, Palmer M, Hoddinott G, Viljoen L, CATALYST Trial Team.   +18 more
europepmc   +1 more source

Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria. [PDF]

Int J Mol Sci
Liu K, Buitenhek E, Kuijl CP, Mulla Y, Luirink J, Bald D.   +5 more
europepmc   +1 more source

A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB). [PDF]

Trials
Mlyuka HJ, Liyoyo A, Nyaulingo B, Mpolya E, Kaswaga OL, Semvua H, Lwambura S, McHugh TD, Wildner L, Sabiiti W, Adegbite BR, Nliwasa M, Khosa C, Mbelele P, Mbeya B, Jeremiah K, Boeree MJ, Gillespie SH, Sloan DJ, Mpagama SG, SimpliciTB Consortium.   +20 more
europepmc   +1 more source